Wellcome Trust Centre for Human Genetics Selects GenoLogics Solution to Manage Sequencing Data
News Jan 20, 2009
The Wellcome Trust Centre for Human Genetics (WTCHG) undertakes research into the genetic basis of multi-factorial diseases such as hypertension, diabetes, heart disease, infectious diseases, psychiatric disorders and multiple sclerosis.
The Genomics Group of the Centre not only conducts research and development, but also provides a number of services for the Centre and other University of Oxford groups. Areas of interest include microarray, high-throughput quantitative gene expression, high-throughput genotyping and other specialties.
According to Dr. Ioannis Ragoussis, Head of Genomics at the Wellcome Trust Centre for Human Genetics, “we selected Geneus for our centralized lab and data management platform because of its flexibility to automate data capture from a wide range of genomics instruments and applications, while allowing us to more efficiently track samples and QC results across numerous projects.” Dr. Ragoussis went on to say, “a primary consideration in our selection of Geneus was the platform’s capability to fully integrate to our next generation sequencing instruments from Illumina and Roche, and automatically pipeline data for downstream analysis.”
Since Geneus is designed for the needs of genomics research facilities, the lab and data management solution to provide the Centre with immediate value. Pre-configured integrations across many instruments, including Illumina’s Genome Analyzer, means Geneus will improve the efficiency of the Centre as well as the quality of the data. This includes configuring the system for range of applications such as ChIP sequencing, resequencing, whole genome sequencing and genome wide association studies. By using GenoLogics’ web collaboration tool, LabLink, and adaptive reporting engine, the Centre will also be able to generate and share results with its customers.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE